Randomized, Double-Blind, Phase 2 Study to Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines At Different Antigen Dose Levels Adjuvanted with AS03® or MF59®
Latest Information Update: 12 Dec 2024
At a glance
- Drugs Influenza A H5N8 vaccine-Seqiris (Primary) ; AS03A; MF 59
- Indications Influenza A virus H5N8 subtype
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 10 Dec 2024 Status changed from recruiting to active, no longer recruiting.
- 04 Sep 2024 Status changed from not yet recruiting to recruiting.
- 24 Aug 2024 New trial record